TO THE EDITOR
Based on murine studies that demonstrate the induction of anti-AML immunity following vaccination with autologous leukaemia cells engineered to express immunomodulatory cytokines and costimulatory molecules, and on promising early reports of this approach being tested in other human malignancies, we and others have commenced human trials of autologous cellular vaccination in primary and MDS-related AML. We have explored the use of adenoviral vectors for producing such vaccines.
Gene transfer by adenoviral vectors of the most commonly used serotypes -types 2 and 5 -is known to comprise a sequential, multistep process. 1 Blocking studies with neutralizing antibodies and peptides have shown that the first step -viral attachment -is mediated by the binding of the adenoviral fibre protein to the coxsackievirus and adenovirus receptor (CAR) (or to other cell surface molecules in the case of vectors bearing modified fibre proteins), while the subsequent steps -viral internalization and intracellular viral DNA release by endosome rupture -require the interaction of a distinct adenoviral protein, the penton base, with a v integrins. 1 As the overall efficiency of adenoviral gene transfer is dependent on each of these sequential steps, adenoviral infection can be impaired by both low-level CAR or a v integrin expression.
Normal primitive haematopoietic progenitors reportedly do not express adenoviral receptors and as a result are believed to be infected inefficiently by adenoviral vectors. 2 Indeed, this reported relative resistance of CD34 þ haematopoietic precursors to adenoviral infection, compared with the ease with which various carcinoma cells can be infected, has been proposed as the basis for a potential adenovirus-mediated stem cell autograft purging strategy for patients with carcinoma undergoing stem cell transplantation. Although the cell surface expression of CAR and of the a v integrins by AML blasts has not been defined, by analogy with their normal CD34 þ counterparts, these cells have similarly been presumed to be nonpermissive for adenoviral gene transfer strategies.
Notably, however, we and others have observed that AML cells can indeed be infected readily with adenoviral vectors, albeit with markedly variable efficiency (reported transduction efficiencies range from 0 to 83% 3 among investigators, and demonstrate marked intrastudy variability as well 3 ). The basis for this variability has not been defined. We reasoned that the susceptibility of AML blasts to adenoviral gene transfer might reflect variable expression of the molecules known to govern adenoviral attachment (CAR), internalization (integrins a v b 3 and a v b 5 ) and intracellular viral DNA release (integrin a v b 5 ). 1 In cells expressing high levels of these molecules, such as HeLa cells, adenovirus-mediated gene transfer is very efficient, and requires only a low virus/cell ratio (MOI) and a short viral incubation time. In contrast, in cells with absent or weak expression, such as lymphocytes, adenoviral infection is inefficient and requires a high MOI and a long viral incubation time (and the use of cationic polymer or lipid transfection adjuvants, or the addition of haematopoietic growth factors, in some cases 3 ). We therefore assessed the cell surface expression of CAR and of the integrins (clone P1F6) and CD45 (clone 2D1). Expression levels were quantified as the ratio of mean fluorescence (RMF; the mean fluorescence intensity following specific mAb binding divided by the mean fluorescence obtained with the appropriate isotype control) and percentage positivity, relative to isotype control staining. We observed that leukaemic blasts did express adenoviral receptor molecules, but that expression varied greatly among patients, with the expression of integrin a v b 5 (median 50.0%; range 1.9-93.4%) exceeding that of integrin a v b 3 (median 2.0%; range 0.6-63.6%) and of CAR (median 1.4%; 0.4-75.7%) (Figures 1 and 2 ).
To address whether gene transfer efficiency was defined by this pattern of receptor expression, we additionally performed adenoviral transductions in a subset of 15 consecutive patients using Ad5.CMV.B7.1. Transduction efficiencies were estimated by the detection of CD80 by flow cytometry 48 h after infection. To ensure that the observed transduction efficiencies would reflect only baseline CAR and integrin expression, and not other experimental manipulations (possibly resulting in receptor-independent virus uptake), haematopoietic growth factors and infection adjuvants were not used. In addition, the relatively low virus/cell ratio used, MOI 300, was chosen based on prior virus titration studies, ensuring that CARmediated mechanisms of virus attachment were not surpassed. Resultant transduction efficiencies ranged from 1.2 to 83.0% ( Figure 1 ) and correlated strongly with the expression of integrin a v b 5 on leukaemic blasts (Po0.0001; Figure 1a ). Adenovirus-mediated gene transfer was also associated to a lesser degree with the expression of CAR (Po0.02; Figure 1b ), but not with the expression of integrin a v b 3 (NS; Figure 1c) . Thus, consistent with the multistep nature of adenoviral infection, the infection efficiency of AML cells is defined not merely by viral attachment, but by internalization as well. Indeed, preincubation of a v b 5 þ AML cells with the a v b 5 blocking mAb P1F6 (but not with control antibodies) reduced adenoviral gene transfer by B60% (not shown), consistent with previous observations in other a v -dependent systems. 1 Our observations thus indicate not only that AML cells express higher levels of integrin a v b 5 than of a v b 3 but also that the former is predictive of adenoviral transduction efficiency, while the latter is not. Curiously, in some other cell types expressing both a v integrins, adenoviral transduction efficiency has been shown to correlate with the expression of a v b 3 . 4 It is likely therefore that the relative importance of individual a v integrins in adenoviral infection varies in a cell-type-specific manner, with distinct integrins subserving overlapping functions in viral entry. Nevertheless, the functions of these two integrins in adenoviral transfection are likely not fully redundant: although adenoviral internalization into target cells can be mediated by both integrin a v b 5 and integrin a v b 3 , integrin a v b 5 also selectively facilitates downstream events such as intracellular virus DNA release by endosome rupture. 1 Looking to account for the observed heterogeneity in blast adenoviral receptor expression and the concomitant variability in adenoviral gene transfer efficiency (Figure 1) , we asked whether the observed differences in receptor expression and gene transfer might define distinct clinical groups that had been pooled in our initial analysis. Haematological parameters did not differ among high and low integrin a v b 5 expressors. Interestingly, however, AML patients with prior MDS were significantly over-represented in the poorly transducable group. Specifically, while baseline CD80 expression was similarly low in both groups, the transduction efficiency of AML samples with prior MDS was 4.974.5% compared to 35.1728.2% for those without prior MDS (Po0.004; Figure 2a) . Similar results were obtained using AdGFP, an adenoviral vector expressing jellyfish green fluorescent protein (not shown), indicating that this phenomenon was unlikely to be related to the transgene used. Notably, blasts from AML patients with prior MDS expressed significantly less integrin a v b 5 (34.0722.4% vs 63.8725.2%; Po0.001; Figure 2b ) and CAR (0.970.8% vs 12.2719.8%; Po0.003; Figure 2c ), than did those from patients without prior MDS. Integrin a v b 3 expression -not correlating with gene transfer efficiency -did not differ significantly between patients with (3.775.4%) and without (8.2714.4%) prior MDS (NS, Figure 2d ). In view of the chromosomal locations of the corresponding loci (integrin a v , 2q31; integrin b 5 , 3q21.2; integrin b 3 , 17q21.32; CAR, 21q11.2), it is unlikely that these differences in expression merely reflect common MDS cytogenetic abnormalities, which most frequently involve chromosomes 5q and 7q. It is more likely that this finding reflects true, but as yet undefined, differences in the biology of MDS and AML, underscoring the marked biological and clinical heterogeneity of this disease group. The basis for the differential expression of the adenoviral receptors in MDS-related and primary AML is not known, but may reflect disease-specific transcriptional dysregulation. Expression of the b 5 integrin gene, for example, is known to be upregulated by TGFb. 5 In MDSrelated AML, however, TGFb signalling is impaired due to both markedly decreased expression of the high-affinity TGFb receptor and signalling defects downstream of the receptor. 6 One can speculate, therefore, that these signalling defects might result in decreased b 5 integrin expression. The consequences of altered expression of adenovirus receptors in AML and MDS are also unclear. The a v integrins -and more recently CAR as wellare known to function as cell adhesion molecules that mediate cell:cell and cell:matrix interactions, thereby playing critical roles in cell development, differentiation and survival. The integrins, furthermore, are known to demonstrate expression patterns that vary with developmental stage and with tumour progression, and CAR has recently been shown to mediate a growth-inhibitory effect in human bladder cancer cells. 7 One can envision various scenarios, therefore, in which altered expression of CAR and of the a v integrins could modulate the behaviour of MDS haematopoietic cells and their interactions with the marrow microenvironment.
The observations reported here have obvious implications for adenovirus-based gene transfer strategies. First, in conditions such as AML -characterized by variable receptor expression and heterogeneous transduction efficiency -the use of a single infection protocol geared towards maximal transduction in the setting of low-level receptor expression, may result in inferior vaccine production in some cases. Specifically, it has been shown in several cell types, including haematopoietic cells, that a high adenoviral MOI that is suitable in receptor low cases may inadvertently result in reduced efficiency in receptor high cases, possibly due to toxicity. 8 The flow cytometric assessment of adenoviral receptor status, therefore, may prove invaluable in optimizing adenoviral gene transfer in AML, especially in light of the recent observation that it may become possible to induce the expression of adenoviral receptors in haematopoietic cells using histone deacetylase inhibitors such as FK228. 8 While the apparent simplicity of this latter strategy is very attractive, it is notable that even an MOI of 50 -too low for efficient infection in a receptor low setting in the absence of FK228 -proved inappropriately high following drug in a receptor high setting, resulting in reduced efficiency compared to an even lower MOI. 8 Thus, even this strategy could be optimized by the pretreatment assessment of the patient's adenoviral receptor expression. Second, our data also suggest caution in the use in AML of CAR-bypassing retargeted adenoviral vectors bearing modified fibre proteins. While such vectors may facilitate viral attachment in cases with low or absent levels of CAR, their ability to mediate efficient gene transfer in a v b 5 integrin low/ absent cases remains unclear.
In conclusion, we have shown that the previously unexplained variability in adenoviral gene transfer efficiency of AML cells is related to interpatient variability in expression of adenoviral receptors, and that AML arising in the setting of MDS defines a distinct disease subgroup with unusually low integrin a v b 5 and CAR expression. These observations not only indicate that patient history and receptor expression (and in particular that of integrin a v b 5 ) represent important and interrelated considerations in any adenovirus-based AML vaccination strategy, but also may provide a new insight into the distinct biologies of de novo and MDS-related AML.
